Literature DB >> 11778810

An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis.

M F Ellis1, M Daniell.   

Abstract

PURPOSE: To evaluate the safety and efficacy of botulinum toxin type A (BOTOX, Allergan) when used to produce a protective ptosis in patients where a surgical tarsorrhaphy would otherwise be required.
METHODS: A total of 21 patients entered into the study. Doses of 2.5 and 5.0 units of BOTOX were injected into the levator palpebrae superioris muscle through the eyelid. The patients were followed daily where practical until a ptosis developed and then monitored 1-2 weekly until the ptosis was resolved. Injections were repeated, if necessary until the underlying condition had healed.
RESULTS: Ptosis took an average +/- SE of 4.0 +/- 0.5 days to develop (range 2-8 days). Duration of ptosis was an average +/- SE of 46.0 +/- 12.1 days (range 1-206 days). The effective dosage was 5 units of BOTOX in 0.1 mL. In 16 patients, the ptosis produced by BOTOX was sufficient to allow the underlying disease to heal and a surgical tarsorrhaphy was avoided. One patient required a surgical tarsorrhaphy and three patients required other surgical intervention to correct the underlying condition. One patient was lost to follow up. Diplopia was seen in five patients but resolved in all cases.
CONCLUSIONS: BOTOX was a suitable alternative to a surgical tarsorrhaphy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11778810     DOI: 10.1046/j.1442-9071.2001.d01-28.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  17 in total

1.  Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group.

Authors:  Valerie P J Saw; Darwin Minassian; John K G Dart; Andrew Ramsay; Hugo Henderson; Stefan Poniatowski; Ruth M Warwick; Suzanne Cabral
Journal:  Br J Ophthalmol       Date:  2007-02-21       Impact factor: 4.638

2.  [Botulinum toxin injection for production of ptosis].

Authors:  R-L Merté; I M Lanzl
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

3.  Use of Botulinum Toxin in Ophthalmology.

Authors:  Michael J Wan; Sara AlShaker; David G Hunter
Journal:  Handb Exp Pharmacol       Date:  2021

4.  Adverse Events Associated With Botox as Reported in a Food and Drug Administration Database.

Authors:  Salma Ahsanuddin; Savannah Roy; Wissam Nasser; Roman Povolotskiy; Boris Paskhover
Journal:  Aesthetic Plast Surg       Date:  2020-10-30       Impact factor: 2.326

5.  Evaluation of efficacy and safety of botulinum toxin type A injection in patients requiring temporary tarsorrhaphy to improve corneal epithelial defects.

Authors:  Abolfazl Kasaee; Mohammad Reza Musavi; Syed Ziaeddin Tabatabaie; Mohammad Nasser Hashemian; Shahrzad Mohebbi; Alireza Khodabandeh; Mohammad Taher Rajabi
Journal:  Int J Ophthalmol       Date:  2010-09-18       Impact factor: 1.779

6.  Putting the Pieces Back Together: Optimizing Function and Appearance after Orbital Surgery.

Authors:  Kimberly Cockerham; Jacquelyn Laplant
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-22

7.  Noncosmetic periocular therapeutic applications of botulinum toxin.

Authors:  Pelin Kaynak-Hekimhan
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

8.  Facial nerve palsy: providing eye comfort and cosmesis.

Authors:  Adel H Alsuhaibani
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

9.  Botulinum toxin type A in the healing of chronic lesion following bilateral spasticity of gluteus muscle.

Authors:  Emanuele Cigna; Michele Maruccia; Benedetta Fanelli; Nicolò Scuderi
Journal:  Int Wound J       Date:  2012-10-19       Impact factor: 3.315

10.  Rate of epithelialisation and re-operations in corneal ulcers treated with amniotic membrane transplantation combined with botulinum toxin-induced ptosis.

Authors:  Thomas Fuchsluger; Emre Tuerkeli; Henrike Westekemper; Joachim Esser; Klaus-Peter Steuhl; Daniel Meller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-12       Impact factor: 3.535

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.